InsidersTradesSigma
申报总数
公司
▲ 买入（4 笔）
▼ 卖出（0 笔）
内部人交易记录
董事已披露买入
4
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Explore the detailed record of transactions filed by Hombach Robert J., 董事. Insider active across 7 companies, notably Biomarin Pharmaceutical INC. Aggregated, 18 filings have been published. Breakdown: 4 buys · 0 sell. Total volume traded: €217k. History available since 25 May 2021. The latest transaction was filed on 12 August 2026 (Acquisition). Regulator: SEC (Form 4). All data is accessible without signup.
Companies and markets linked to Hombach Robert J.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报18 总计
45,000 股@ US$4.9744Common StockSEC:0000947871-26-000786:0
标准退出：2026年11月10日 (T+90)
13,000 股Common StockSEC:0001193125-26-280175:0
标准退出：2026年9月20日 (T+90)
7,490 股0Common StockSEC:0001628280-26-040916:0
2,577 股0Common Stock par value $0.01 per shareSEC:0001496182-26-000002:0
22,841 股0Common StockSEC:0000947871-26-000164:0
6,650 股0Common StockSEC:0001048477-25-000074:0
2,844 股0Common Stock par value $0.01 per shareSEC:0000950170-25-034740:0
13,839 股0Common StockSEC:0000947871-25-000184:0
4,720 股0Common StockSEC:0001048477-24-000106:0
11,455 股0Common StockSEC:0000947871-24-000108:0
4,190 股0Common StockSEC:0001209191-23-031971:0
6,979 股0Common StockSEC:0001209191-23-008441:0
4,980 股0Common StockSEC:0001567619-22-011794:0
6,024 股0Common StockSEC:0001209191-22-023177:0
5,400 股@ US$2.4025.0% 占其流量Common StockSEC:0001415889-21-005223:0
标准退出：2022年2月9日 (T+90)
5,400 股@ US$2.40100.0% 占其流量Common StockSEC:0001415889-21-005202:0
标准退出：2022年2月9日 (T+90)
1,308 股0Common StockSEC:0001170010-21-000150:0
5,120 股0Common StockSEC:0001567619-21-011309:0
18 条申报中的 18 条
About Hombach Robert J.
HOMBACH ROBERT J. is Administrateur and a declarant, with 17 filings in total. Across the 17 sampled filings, the reported buy amount is 22567 EUR and the reported sell amount is 0, covering the period from 2021-05-27 to 2026-06-24. The companies mentioned are Biomarin Pharmaceutical INC, Embecta Corp., Henry Schein INC, Aptinyx Inc., Seaport Therapeutics, Inc. and CARMAX INC, and the stated transaction nature is Attribution.
